Skip to main content
Top
Published in: Gastric Cancer 1/2018

01-01-2018 | Special Article

The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging

Authors: Haejin In, Ethan Ravetch, Marisa Langdon-Embry, Bryan Palis, Jaffer A. Ajani, Wayne L. Hofstetter, David P. Kelsen, Takeshi Sano

Published in: Gastric Cancer | Issue 1/2018

Login to get access

Abstract

Purpose

New stage grouping classifications for clinical (cStage) and post-neoadjuvant treatment (ypStage) stage for gastric adenocarcinoma have been proposed for the eighth edition of the AJCC manual. This article summarizes the analysis for these stages.

Methods

Gastric adenocarcinoma patients diagnosed in 2004–2009 were identified from the National Cancer Database (NCDB). The cStage cohort included both surgical and nonsurgical cases, and the ypStage cohort included only patients who had chemotherapy or radiation therapy before surgery. Survival differences between the stage groups were determined by the log-rank test and prognostic accuracy was assessed by concordance index. Analysis was performed using SAS 9.4 (SAS, Cary, NC, USA).

Results

Five strata for cStage and four strata for ypStage were developed. The 5-year survival rates for cStages were 56.77%, 47.39%, 33.1%, 25.9%, and 5.0% for stages I, IIa, IIb, III, and IV, respectively, and the rates for ypStage were 74.2%, 46.3%, 19.2%, and 11.6% for stages I, II, III, and IV, respectively. The log-rank test showed that survival differences were well stratified and stage groupings were ordered and distinct (p < 0.0001). The proposed cStage and ypStage classification was sensitive and specific and had high prognostic accuracy (cStage: c index = 0.81, 95% CI, 0.79–0.83; ypStage: c index = 0.80, 95% CI, 0.73–0.87).

Conclusion

The proposed eighth edition establishes two new staging schemata that provide essential prognostic data for patients before treatment and for patients who have undergone surgery following neoadjuvant therapy. These additions are a significant advance to the AJCC staging manual and will provide critical guidance to clinicians in making informed decisions throughout the treatment course.
Appendix
Available only for authorised users
Literature
5.
go back to reference American Joint Committee. Manual for staging of cancer. 1st edn. Chicago: American Joint Committee for Cancer Staging and End Results Reporting; 1977. American Joint Committee. Manual for staging of cancer. 1st edn. Chicago: American Joint Committee for Cancer Staging and End Results Reporting; 1977.
6.
go back to reference Ajani JA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric-carcinoma. J Natl Cancer Inst. 1993;85(22):1839–44.CrossRefPubMed Ajani JA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric-carcinoma. J Natl Cancer Inst. 1993;85(22):1839–44.CrossRefPubMed
7.
go back to reference Ajani JA, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–80.CrossRefPubMed Ajani JA, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–80.CrossRefPubMed
8.
go back to reference Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14(2):97–100.CrossRefPubMed Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14(2):97–100.CrossRefPubMed
10.
go back to reference Bilimoria KY, Stewart AK, Winchester DP, Clifford KY. The National Cancer Center Database: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.CrossRefPubMedPubMedCentral Bilimoria KY, Stewart AK, Winchester DP, Clifford KY. The National Cancer Center Database: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.CrossRefPubMedPubMedCentral
11.
go back to reference Commission on Cancer of the American College of Surgeons. Facility oncology registry data standards revised for 2016. Chicago, IL: American College of Surgeons; 2016. Commission on Cancer of the American College of Surgeons. Facility oncology registry data standards revised for 2016. Chicago, IL: American College of Surgeons; 2016.
12.
go back to reference Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109–23.CrossRefPubMed Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109–23.CrossRefPubMed
13.
go back to reference Liu L, Forman S, Barton B (2009) Fitting Cox model using PROC PHREG and beyond in SAS. SAS Global Forum. March 22-25 2009; Washington, DC. Liu L, Forman S, Barton B (2009) Fitting Cox model using PROC PHREG and beyond in SAS. SAS Global Forum. March 22-25 2009; Washington, DC.
14.
go back to reference American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. Heidelberg: Springer; 2017. p. 1024. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. Heidelberg: Springer; 2017. p. 1024.
15.
go back to reference Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, Terashima M (2017) Impact of clinical tumor-node-metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer 20(3):448–456. doi:10.1007/s10120-016-0637-x.CrossRefPubMed Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, Terashima M (2017) Impact of clinical tumor-node-metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer 20(3):448–456. doi:10.​1007/​s10120-016-0637-x.CrossRefPubMed
17.
go back to reference Ajani JA, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23(6):1237–44.CrossRefPubMed Ajani JA, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23(6):1237–44.CrossRefPubMed
18.
go back to reference Rohatgi PR, et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer (Phila). 2006;107(7):1475–82.CrossRef Rohatgi PR, et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer (Phila). 2006;107(7):1475–82.CrossRef
19.
go back to reference Wittekind C, Compton C, Brierley J, Sobin LH. TNM Supplement. 4th edn. Hoboken NJ: Wiley-Blackwell; 2012. Wittekind C, Compton C, Brierley J, Sobin LH. TNM Supplement. 4th edn. Hoboken NJ: Wiley-Blackwell; 2012.
Metadata
Title
The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging
Authors
Haejin In
Ethan Ravetch
Marisa Langdon-Embry
Bryan Palis
Jaffer A. Ajani
Wayne L. Hofstetter
David P. Kelsen
Takeshi Sano
Publication date
01-01-2018
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 1/2018
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-017-0765-y

Other articles of this Issue 1/2018

Gastric Cancer 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.